Clinical trials: Cohort
Seizures
Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
This is a multi-center, non-interventional and prospective study of patients receiving Epidyolex as part of standard clinical practice in France.
- Trial name
- OPERA (NCT05772429)
- Testing
- Epidiolex
- Where
- 29 sites in France
- Volunteers
- 158 people
- Sponsor
- Jazz Pharmaceuticals
Malformations
Varenicline Pregnancy Cohort Study
A prospective population-based cohort study to examine whether varenicline use during pregnancy is associated with an increased risk of major congenital malformations in infants above that associated with smoking during pregnancy.
- Trial name
- NCT01290445
- Testing
- varenicline, cigarette smoke from maternal smoking, Non-Exposure
- Volunteers
- 885,185 people
- Sponsor
- Pfizer
X-linked Hypophosphatemia (XLH)
Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia
The purpose of this study is to better understand how X-linked hypophosphatemia (XLH) affects the body and daily life. Phosphate levels are critical in managing XLH, we aim to study how these levels change in patients taking…
- Trial name
- IBIS XLH (NCT07607600)
- Testing
- No treatment given
- Where
- 23 sites in United States, Australia and 6 more
- Sponsor
- Novo Nordisk A/S
Normal Healthy
Topical Multiple Ascending Dose Study for PF-06423264
The current study is the first clinical trial proposed with PF-06423264. It is designed to evaluate the safety, tolerability, and pharmacokinetics (PK) following administration of multiple ascending doses of PF-06423264 to…
- Trial name
- NCT02778477
- Testing
- PF-06423264
- Where
- Belgium
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Pfizer
Anterior Cruciate Ligament Injuries
A Prospective Cohort Post Market Registry Evaluating Outcomes of Bridge-Enhanced ACL Restoration (BEAR®)
The purpose of the Bridge Registry is to assess real-world performance of the FDA approved BEAR Implant.
- Trial name
- NCT05398341
- Testing
- The BEAR® Implant
- Where
- 8 sites in United States
- Volunteers
- 300 people
- Sponsor
- Miach Orthopaedics
Safety
Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4
A Phase 1 study of the safety, tolerability, and pharmacokinetics of a new oxazolidinone antibiotic. In Part 1 cohorts of healthy adults will participate in a single dose escalation study of increasing intravenous doses of MRX-4.
- Trial name
- NCT03033329
- Testing
- Single intravenous doses of MRX-4, Multiple intravenous doses of MRX-4, Single dose of intravenous and oral MRX-4
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- MicuRx
Solid Tumors
A Study of ERY974 in Patient With Advanced Solid Tumors
This is the open label, multicenter Phase 1 study which consists of a dose escalation to determine the maximum tolerated dose (MTD) and cohort expansion to obtain a preliminary evaluation of anti-tumor activity.
- Trial name
- NCT02748837
- Testing
- ERY974
- Where
- 10 sites in United States, France and 1 more
- Volunteers
- 29 people
- Sponsor
- Chugai Pharmaceutical
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study of NEO-201 in Solid Tumors Expansion Cohorts
The open label, first-in-human, phase 1, dose escalation component in refractory solid tumors has been completed. The Maximum Tolerated Dose and Recommended Phase 2 Dose (RP2D) was determined to be 1.5mg/kg.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer, Uterine Cancer
- Trial name
- NCT03476681
- Testing
- NEO-201 in combination with pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 121 people
- Sponsor
- Precision Biologics, Inc
Solid Tumor, Adult
A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy
The drug that will be investigated in the study is GEN1053. GEN1053 is an antibody designed to (re)activate and increase antitumor immunity.
- Trial name
- NCT05435339
- Testing
- GEN1053
- Where
- 5 sites in United States, Spain
- Volunteers
- 31 people
- Sponsor
- Genmab
Non-Hodgkin Lymphoma, Hodgkin Disease
The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)
Participants with non-Hodgkin lymphoma (NHL) or Hodgkin disease (HD) will be assigned to one of 2 arms based on the immunophenotype of their lymphoma.
- Trial name
- NCT00444912
- Testing
- G-CSF plus plerixafor, rituximab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Genzyme, a Sanofi Company
Depression, Suicide
Antidepressant Drug Exposure and Risk of Suicide Attempt Resulting in Medical Intervention in US Adults
The primary objective of the study is to estimate the incidence of suicide attempts resulting in a medical encounter or hospitalization in seven propensity matched cohorts of subjects: patients treated with duloxetine for…
- Trial name
- NCT00763724
- Volunteers
- 254,432 people
- Sponsor
- Eli Lilly and Company
Healthy
A Relative Bioavailability and Food Effect Study of TYRA-300-B01 Capsule and Tablet Formulations in Healthy Adult Participants
The purpose of this study is to evaluate the relative bioavailability of capsule and tablet formulations of TYRA-300-B01, and to evaluate the safety, tolerability, and food effect of TYRA-300-B01 tablets in healthy adult…
- Trial name
- NCT06006702
- Testing
- TYRA-300-B01
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Tyra Biosciences, Inc
Median Sternotomy
Study to Evaluate the Safety and Efficacy of Dermal Injections of JVS-100 Given to Adults Receiving Median Sternotomy
This study will investigate the safety and efficacy of using JVS-100 to accelerate wound healing and reduce scar formation in subjects receiving surgical incisions ("sternotomies") during cardiovascular surgery.
- Trial name
- NCT01657045
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- SironRX Therapeutics, Inc.
Brain Concussion
Blood Biomarker Study to Diagnose Adolescent Sport Concussion
Concussions are one of the most complex conditions to manage in sport medicine due to the individualized clinical presentation, caused by a complex neurometabolic cascade, and the lack of a diagnostic standard.
- Trial name
- NCT05287997
- Testing
- Neurolytixs Index
- Where
- 2 sites in United States, Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Neurolytixs
Rheumatoid Diseases, Rheumatoid Arthritis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade
To assess persistence of CT-P13 in patients with Rheumatoid Diseases (Rheumatoid arthritis [RA], ankylosing spondylitis [AS], and psoriatic arthritis [PsA]) who are naïve to biologics or are switching from stable Remicade to…
- Conditions
- Rheumatoid Diseases, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- PERSIST (NCT02605642)
- Testing
- CT-P13
- Where
- 38 sites in Bulgaria, Canada and 5 more
- Volunteers
- 351 people
- Sponsor
- Pfizer
COVID-19
Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19
Sotrovimab binds to a conserved epitope on the severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 spike protein outside the receptor-binding motif and has been shown to reduce the risk of hospitalization…
- Trial name
- LUNAR (NCT05305651)
- Testing
- Sotrovimab
- Where
- 8 sites in United Kingdom
- Volunteers
- 217 people
- Sponsor
- GlaxoSmithKline
Propionic Acidemia
A Retrospective Study to Characterize Participants With Propionic Acidemia
This is a non-interventional, observational, global, multicenter, study describing participant characteristics, clinical outcomes, and event rates in participants with propionic acidemia (PA).
- Trial name
- NCT05769621
- Where
- 29 sites in United States, Australia and 7 more
- Volunteers
- 60 people
- Sponsor
- ModernaTX, Inc.
Glioblastoma
Assessment of a Large US EHR Database as Meeting FDA Fit-for-Purpose Requirements to Provide External Controls for Study BPM31510 in Participants With Glioblastoma
Glioblastoma is a rare, aggressive brain tumor that leads to death within 2 years of diagnosis in more than half of patients. There are currently 123 studies ongoing that are testing treatments for glioblastoma.
- Trial name
- NCT07674095
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- BPGbio
Mammographic Breast Density
Topical Endoxifen in Women
Karma CREME-1 consisted of 90 participants from the Karma Cohort. The major focus of the pilot trial was to estimate time to mammographic density change.
- Trial name
- CREME (NCT04616430)
- Testing
- Topical endoxifen
- Where
- Sweden
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Atossa Therapeutics, Inc.
Arthritis
PyroTITAN Humeral Resurfacing Arthroplasty (HRA)
The study is designed as a single center, post-market, non-randomized, open-label, observational clinical study with retrospective and prospective enrollment to evaluate the 2-year post implantation survivorship of the PyroTITAN™…
- Trial name
- HRA (NCT02983292)
- Testing
- PyroTITAN™ HRA
- Where
- Australia
- Volunteers
- 137 people
- Sponsor
- Smith & Nephew, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.